Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.

Antonio RussoMarcello SilvestroFabrizio Scotto di ClementeFrancesca TrojsiAlvino BiseccoSimona BonavitaAlessandro TessitoreGioacchino Tedeschi

Published in: The journal of headache and pain (2020)

These real-world data support monthly erenumab 70 or 140 mg s.c. as a safe and effective preventive treatment to reduce headache frequency and severity in chronic migraine patients experiencing previous unsuccessful preventive treatments.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
electronic health record
patient reported outcomes
deep learning
replacement therapy
artificial intelligence
psychometric properties